MYOS RENS Technology Inc. (MYOS) Analysts See $-0.08 EPS

July 14, 2018 - By Margaret Guttierez

Analysts expect MYOS RENS Technology Inc. (NASDAQ:MYOS) to report $-0.08 EPS on August, 13.They anticipate $0.11 EPS change or 57.89 % from last quarter’s $-0.19 EPS. After having $-0.19 EPS previously, MYOS RENS Technology Inc.’s analysts see -57.89 % EPS growth. The stock decreased 7.43% or $0.11 during the last trading session, reaching $1.37. About 246,990 shares traded or 14.28% up from the average. MYOS RENS Technology Inc. (NASDAQ:MYOS) has declined 27.80% since July 14, 2017 and is downtrending. It has underperformed by 40.37% the S&P500.

MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company has market cap of $10.24 million. The firm primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. It currently has negative earnings. The Company’s products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes.

More news for MYOS RENS Technology Inc. (NASDAQ:MYOS) were recently published by:, which released: “38 Stocks Moving In Wednesday’s Mid-Day Session” on July 11, 2018.‘s article titled: “44 Biggest Movers From Yesterday” and published on July 12, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.